Clinical Trials Browser

Terminated × Interventional × sitravatinib × Clear all

NCT04904302 2026-03-16

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2 Terminated

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Phase 2 Terminated

96 enrolled 17 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04123704 2024-08-26

Sitravatinib in Metastatic Breast Cancer

Phase 2 Terminated

3 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2 Terminated

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT05176925 2024-01-29

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03606174 2023-08-24

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

260 enrolled 28 charts

Carcinoma, Transitional Cell